Entelos to provide evaluation services to Bayer AG for asthma drug development

Entelos Inc. (Menlo Park, CA) and Bayer AG (Leverkusen, Germany) have completed at professional services agreement for evaluating an IL-4 receptor antagonist as a potential treatment for asthma. Entelos has thus far applied their predictive asthma PhysioLab technology to Bayer's proprietary animal model data to assess the impact of treatment on a variety of patient types and to develop dose and dose regimens.

"The analysis provided by Entelos has already helped our strategic drug development group to refine the clinical development program for IL-4RA," said Timothy Shannon, head of global medical development at Bayer. "Bayer is always on the watch for innovative new technologies like Entelos PhysioLabs."

Entelos uses its customizable PhysioLab technology to solve client-specific problems. The asthma PhysioLab, for example, is a comprehensive, proprietary disease simulation system that integrates relevant biological processes for predictive applications in asthma drug discovery, development, and commercialization. With Entelos Asthma PhysioLab, scientists can explore the physiologic mechanisms contributing to asthma and possible therapies to treat the disease. Bayer is the latest major pharmaceutical company to enjoy the benefits of Entelos' PhysioLab through subscriptions, development partnerships, or professional services offered by Entelos.

"With this project, our professional services group was able to demonstrate some of the basic capabilities of the asthma PhysioLab and our expert consultants in addressing critical drug development issues for pharmaceutical and biotech companies today," stated James M. Karis, president and CEO of Entelos.

For more information, contact Cathy Crane Moley, VP of corporate development at Entelos Inc., at 650-330-5200.

Edited by Angelo DePalma
Managing Editor, Drug Discovery Online
adepalma@drugdiscoveryonline.com